| Budget Amount *help |
¥4,810,000 (Direct Cost: ¥3,700,000、Indirect Cost: ¥1,110,000)
Fiscal Year 2016: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2015: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
Fiscal Year 2014: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
|
|---|
| Outline of Final Research Achievements |
This study aimed to elucidate the molecular pathology of overlap syndrome of asthma and COPD. Among the inflammation biomarkers assessed, peripheral blood eosinophil count, exhaled NO fraction, exhaled breath condensate IP - 10 increased with asthma and overlap syndrome. It was confirmed that exhaled NO fraction is a useful marker for predicting improvement of airflow limitation and COPD assessment test (CAT) by steroid therapy. It was shown that central expiratory NO and peripheral exhaled NO have equivalent sensitivity and specificity. We also observed that the existence of severe exacerbations and persistently high level of exhaled NO fraction are associated with the rapid progression of airflow limitation in observational studies for asthma.
|
